NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Solaris Energy Infrastructure, Inc. (NYSE: SEI). Shareholders who purchased shares of SEI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/solaris-energy-infrastructure-inc-loss-submission-form/?id=147132&f ...

NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Avis Budget Group, Inc. (NASDAQ: CAR). Shareholders who purchased shares of CAR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/avis-budget-loss-submission-form/?id=147119&from=3 CLASS PERIOD: February 16, ...

Core Viewpoint - Treace Medical Concepts, Inc. is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its primary product, the 3D bunion correction system, "Lapiplasty" [3]. Summary by Relevant Sections Company Performance - The lawsuit claims that competition negatively affected the demand and utilization of Treace Medical's primary product, leading to a decline in revenue [3]. - The company was required to expedite plans for an alternative product to osteotomy due to the declining performance of its existing offerings [3]. Legal Proceedings - The class period for the lawsuit is defined as May 8, 2023, to May 7, 2024 [3]. - Shareholders who purchased shares during this period are encouraged to register for participation in the class action, with a deadline set for June 10, 2025 [4]. Investor Information - The Gross Law Firm is representing the shareholders and aims to protect the rights of investors who have suffered losses due to the alleged misleading statements by Treace Medical [5]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [4].

NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Ibotta, Inc. (NYSE: IBTA). Shareholders who purchased shares of IBTA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/ibotta-loss-submission-form/?id=147115&from=3 CLASS PERIOD: This lawsuit is on behalf of ...

LOS ANGELES, May 7, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Civitas Resources, Inc. ("Civitas" or "the Company") (NYSE: CIVI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics ...

NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BigBear.ai Holdings, Inc. (NYSE: BBAI) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in BigBear.ai, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/bigbearai-holdings-inc. Investors have until June 10, 2025, to ask the Court to be a ...

Core Viewpoint - A lawsuit has been filed against Viatris Inc. and certain senior executives for potential violations of federal securities laws, stemming from misleading statements regarding the company's operational conditions and the impact of a failed FDA inspection [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Western District of Pennsylvania, titled Quinn v. Viatris Inc., et al., No. 25-cv-466, with investors having until June 3, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Viatris securities [2]. Group 2: Company Background and Allegations - Viatris is a global healthcare company that provides medicines to approximately 1 billion patients across over 165 countries [3]. - The complaint claims that Viatris misrepresented its facilities as being in "good operating condition" and suitable for their intended purposes, while downplaying the significance of a Warning Letter issued by the FDA following a failed inspection at its Indore, India facility [3][4]. Group 3: Financial Impact - The failed FDA inspection has had a substantial negative impact on Viatris's financial results, hindering the company from manufacturing and distributing key products, including Lenalidomide [4]. - In the Q4 2024 results released on February 27, 2025, Viatris disclosed that the failed inspection would reduce 2025 revenue by approximately $500 million and earnings from operations by about $385 million [5]. - Following this announcement, Viatris's stock price fell roughly 15%, from $11.24 per share on February 26, 2025, to $9.53 per share on February 27, 2025 [5].

Core Viewpoint - A lawsuit has been filed against The Bancorp, Inc. and its senior executives for potential violations of federal securities laws, specifically related to misrepresentation of risks associated with its loan portfolio [1][2][4]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Delaware, captioned Linden v. The Bancorp, Inc., et al., No. 25-cv-00326, with investors having until May 16, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, representing investors who purchased Bancorp stock [2]. Group 2: Company Overview - Bancorp is a financial holding company involved in institutional banking, commercial real estate bridge lending, small business lending, and commercial fleet leasing, with its REBLs primarily collateralized by apartment buildings [3]. Group 3: Allegations of Misrepresentation - The complaint claims that Bancorp misrepresented the risks of default or loss on its REBL loan portfolio and that its credit loss methodology was inadequate [4]. - It is alleged that Bancorp's internal controls over financial reporting contained at least one material weakness [4]. Group 4: Stock Performance and Impact - Following a report from Culper Research on March 21, 2024, which highlighted misrepresentations regarding the REBL loan portfolio, Bancorp's stock price fell over 10%, from $36.04 to $32.12 [5]. - On October 24, 2024, Bancorp reported a net income of $51.5 million, leading to a 14% decline in stock price from $54.96 to $47.01 due to increased credit losses [6]. - On March 4, 2025, Bancorp disclosed inappropriate filing of its Annual Report, causing a 4.4% drop in stock price from $53.59 to $51.25 [7].

Core Viewpoint - A lawsuit has been filed against Fluence Energy, Inc. and certain senior executives for potential violations of federal securities laws, alleging misrepresentation of the company's competitive position and financial performance [1][2][4]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Eastern District of Virginia, captioned Abramov v. Fluence Energy, Inc., et al., No. 25-cv-00444, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [2]. - Investors have until May 12, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background - Fluence Energy specializes in energy storage products and solutions, delivery services, operational and maintenance services, and digital applications for energy storage and power assets [3]. Group 3: Allegations and Financial Performance - Allegations state that Fluence Energy misrepresented its sales pipeline and backlog, concealing declines in sales and earnings growth through aggressive revenue pull-forwards and selective earnings adjustments [4]. - A report by Blue Orca Capital revealed that Siemens Energy filed a lawsuit against Fluence Energy for misrepresentations and fraud, contributing to a significant decline in stock price [5]. - In Q1 2025, Fluence Energy reported a net loss of $57 million, or $0.32 per share, with revenues falling 49% year-over-year, leading to a 46% drop in stock price to $7.00 per share [6].

Core Viewpoint - A securities class action lawsuit has been filed against Fluence Energy, Inc. for misleading investors regarding its financial health and relationships with major partners during the specified Class Period [1][3]. Group 1: Lawsuit Details - The lawsuit pertains to Fluence securities purchased between October 28, 2021, and February 10, 2025 [1][2]. - Investors have until May 12, 2025, to seek appointment as lead plaintiff representatives [2]. Group 2: Allegations Against Fluence - The lawsuit claims that Fluence misled investors about the stability of its relationships with Siemens AG and The AES Corporation, which are significant sources of revenue [3]. - Allegations include that Siemens accused Fluence of engineering failures and fraud, leading to artificially inflated margins and revenue growth due to the impending decline in these relationships [3].